Greenwhich Pharmaceuticals Inc&lt;GRPI.O> said it has completed a private placement of itscommon stock, generating more than eight mln dlrs in netproceeds.    These funds, together with the two mln dlrs in cashcurrently held by the company, will be used to complete itsTherafectin rheumatoid arthritis drug development program andto develop other drugs, the company said. Reuter&#3;